<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33518565</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1349-7235</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>Internal medicine (Tokyo, Japan)</Title><ISOAbbreviation>Intern Med</ISOAbbreviation></Journal><ArticleTitle>Sporadic Amyotrophic Lateral Sclerosis Due to a FUS P525L Mutation with Asymmetric Muscle Weakness and Anti-ganglioside Antibodies.</ArticleTitle><Pagination><StartPage>1949</StartPage><EndPage>1953</EndPage><MedlinePgn>1949-1953</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2169/internalmedicine.6168-20</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) due to a fused in sarcoma (FUS) P525L mutation is characterized by a rapidly progressive course. Multifocal motor neuropathy (MMN) may resemble ALS in early stage and is associated with anti-ganglioside antibodies. A 38-year-old woman was admitted to our hospital because of progressive muscle weakness in the right limbs. She had mild mental retardation and minor deformities. Initially, we suspected MMN given the asymmetric muscle weakness and detection of anti-ganglioside antibodies. However, physical and electrophysiological tests did not support MMN, instead suggesting ALS. We confirmed a heterozygous P525L mutation and finally diagnosed this case as ALS due to an FUS mutation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tanemoto</LastName><ForeName>Masanobu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sapporo Medical University, School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hisahara</LastName><ForeName>Shin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sapporo Medical University, School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Kazuna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sapporo Medical University, School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokokawa</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sapporo Medical University, School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manabe</LastName><ForeName>Tatsuo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sapporo Medical University, School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuda</LastName><ForeName>Reiko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sapporo Medical University, School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sapporo Medical University, School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsushita</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sapporo Medical University, School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsumura</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sapporo Medical University, School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Syuuichirou</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sapporo Medical University, School of Medicine, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimohama</LastName><ForeName>Shun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Sapporo Medical University, School of Medicine, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Intern Med</MedlineTA><NlmUniqueID>9204241</NlmUniqueID><ISSNLinking>0918-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005732">Gangliosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005732" MajorTopicYN="N">Gangliosides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">P525L mutation</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">anti-ganglioside antibody</Keyword><Keyword MajorTopicYN="N">fused in sarcoma</Keyword></KeywordList><CoiStatement><b>The authors state that they have no Conflict of Interest (COI).</b></CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>1</Day><Hour>5</Hour><Minute>49</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33518565</ArticleId><ArticleId IdType="pmc">PMC8263198</ArticleId><ArticleId IdType="doi">10.2169/internalmedicine.6168-20</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lattante S, Rouleau GA, Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum Mutat 34: 812-826, 2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">23559573</ArticleId></ArticleIdList></Reference><Reference><Citation>Join task force of the EFNS and the PNS. European federation of neurological societies/peripheral nerve society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European federation of neurological societies and peripheral nerve society-first revision.. J Peripher Nerv Syst 15: 295-301, 2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">21199100</ArticleId></ArticleIdList></Reference><Reference><Citation>Pakiam ASI, Parry GJ. Multifocal motor neuropathy without overt conduction block. Muscle Nerve 21: 243-245, 1998.</Citation><ArticleIdList><ArticleId IdType="pubmed">9466602</ArticleId></ArticleIdList></Reference><Reference><Citation>Cats EA, van der Pol WL, Piepers S, et al. . Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 75: 818-825, 2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">20805527</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusunoki S, Chiba A, Kon K, et al. . N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barr&#xe9; syndrome. Ann Neurol 35: 570-576, 1994.</Citation><ArticleIdList><ArticleId IdType="pubmed">8179303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I. Guillain-Barr&#xe9; syndrome with antibody to a ganglioside, N-acetylgalactosaminyl GD1a. Brain 123: 116-124, 2000.</Citation><ArticleIdList><ArticleId IdType="pubmed">10611126</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Usuki S, Quarles B, Rivner MH, Ariga T, Yu RK. Anti-sulfoglucuronosyl paragloboside antibody: a potential serologic marker of amyotrophic lateral sclerosis. ASN Neuro 8: 1759091416669619, 2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5043593</ArticleId><ArticleId IdType="pubmed">27683876</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai SL, Abramzon Y, Schymick JC, et al. . FUS mutations in sporadic amyotrophic lateral sclerosis. Neurobiol Aging 32: 550 (e1-4), 2011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891336</ArticleId><ArticleId IdType="pubmed">20138404</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B, Wang H, Cai Y, et al. . FUS P525L mutation causing amyotrophic lateral sclerosis and movement disorders. Brain Behav 10: e01625, 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7303404</ArticleId><ArticleId IdType="pubmed">32307925</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanleenuwat P, Iwanowski P, Kozubski W. Antiganglioside antibodies in neurological diseases. J Neurol Sci 408: 116576, 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">31726381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaida K, Ariga T, Yu RK. Antiganglioside antibodies and their pathophysiological effects on Guillain-Barr&#xe9; syndrome and related disorders-a review. Glycobiology 19: 676-692, 2009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688390</ArticleId><ArticleId IdType="pubmed">19240270</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoine JC, Camdessanch&#xe9; JP, Ferraud K, Caudie C. Antiganglioside antibodies in paraneoplastic peripheral neuropathies. J Neurol Neurosurg Psychiatry 75: 1765-1767, 2004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738838</ArticleId><ArticleId IdType="pubmed">15548502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaji R, Kusunoki S, Mizutani K, et al. . Chronic motor axonal neuropathy associated with antibodies monospecific for N-acetylgalactosaminyl GD1a. Muscle Nerve 23: 702-706, 2000.</Citation><ArticleIdList><ArticleId IdType="pubmed">10797392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa-Goto K, Funamoto N, Ohta Y, Abe T, Nagashima K. Myelin gangliosides of human peripheral nervous system: an enrichment of GM1 in the motor nerve myelin isolated from cauda equina. J Neurochem 59: 1844-1849, 1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">1402926</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I. GalNAc-GD1a in human peripheral nerve: target sites of anti-ganglioside antibody. Neurology 61: 465-470, 2003.</Citation><ArticleIdList><ArticleId IdType="pubmed">12939418</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariga T. Pathogenic role of ganglioside metabolism in neurodegenerative diseases. J Neurosci Res 92: 1227-1242, 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">24903509</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Suzuki M, Irie T, Watanabe T, Mikami H, Ono S. Amyotrophic lateral sclerosis associated with IgG anti-GalNAc-GD1a antibodies. Clin Neurol Neurosurg 110: 722-724, 2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">18450370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateishi T, Hokonohara T, Yamasaki R, et al. . Multiple system degeneration with basophilic inclusions in Japanese ALS patients with FUS mutation. Acta Neuropathol 119: 355-364, 2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">19967541</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama T, Warita H, Kato M, et al. . Genotype-phenotype relationships in familial amyotrophic lateral sclerosis with FUS/TLS mutations in Japan. Muscle Nerve 54: 398-404, 2016.</Citation><ArticleIdList><ArticleId IdType="pubmed">26823199</ArticleId></ArticleIdList></Reference><Reference><Citation>Groen EJ, van Es MA, van Vught PW, et al. . FUS mutations in familial amyotrophic lateral sclerosis in the Netherlands. Arch Neurol 67: 224-230, 2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">20142531</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Ziemann U, Eisen A, Hallett M, Kiernan MC. Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry 84: 1161-1170, 2013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786661</ArticleId><ArticleId IdType="pubmed">23264687</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu&#xe9;gan C, Vila M, Rosoklija G, Hays AP, Przedborski S. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci 21: 6569-6576, 2001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763092</ArticleId><ArticleId IdType="pubmed">11517246</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollewe K, Wurster U, Sinzenich T, et al. . Anti-ganglioside antibodies in amyotrophic lateral sclerosis revisited. PLoS ONE 10: e0125339, 2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397083</ArticleId><ArticleId IdType="pubmed">25875836</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobsiger CS, Boill&#xe9;e S, Cleveland DW. Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc Natl Acad Sci USA 104: 7319-7326, 2007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1863491</ArticleId><ArticleId IdType="pubmed">17463094</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker DJ, Blackburn DJ, Keatinge M, et al. . Lysosomal and phagocytic activity is increased in astrocytes during disease progression in the SOD1 (G93A) mouse model of amyotrophic lateral sclerosis. Front Cell Neurosci 9: 410, 2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4606544</ArticleId><ArticleId IdType="pubmed">26528138</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodge JC, Treleaven CM, Pacheco J, et al. . Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 112: 8100-8105, 2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4491749</ArticleId><ArticleId IdType="pubmed">26056266</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang EJ, Zhang J, Geser F, et al. . Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions. Brain Pathol 20: 1069-1076, 2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951498</ArticleId><ArticleId IdType="pubmed">20579074</ArticleId></ArticleIdList></Reference><Reference><Citation>Mochizuki Y, Isozaki E, Takao M, et al. . Familial ALS with FUS P525L mutation: two Japanese sisters with multiple systems involvement. J Neurol Sci 323: 85-92, 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">22980027</ArticleId></ArticleIdList></Reference><Reference><Citation>Leblond CS, Webber A, Gan-Or Z, et al. . De novo FUS P525L mutation in juvenile amyotrophic lateral sclerosis with dysphonia and diplopia. Neurol Genet 2: e63, 2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4830191</ArticleId><ArticleId IdType="pubmed">27123482</ArticleId></ArticleIdList></Reference><Reference><Citation>Eura N, Sugie K, Suzuki N, et al. . A juvenile sporadic amyotrophic lateral sclerosis case with P525L mutation in the FUS gene: a rare co-occurrence of autism spectrum disorder and tremor. J Neurol Sci 398: 67-68, 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">30684766</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;umer D, Hilton D, Paine SML, et al. . Jevenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology 75: 611-618, 2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2931770</ArticleId><ArticleId IdType="pubmed">20668261</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita S, Mori A, Sakaguchi H, et al. . Sporadic juvenile amyotrophic lateral sclerosis caused by mutant FUS/TLS: possible association of mental retardation with this mutation. J Neurol 259: 1039-1044, 2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">22057404</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>